Taysha Gene Therapies (TSHA) Consolidated Net Income (2022 - 2025)
Historic Consolidated Net Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.
- Taysha Gene Therapies' Consolidated Net Income fell 2962.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 1565.51%. This contributed to the annual value of -$84.6 million for FY2024, which is 1456.17% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Consolidated Net Income of -$30.9 million as of Q3 2025, which was down 2962.42% from -$24.9 million recorded in Q2 2025.
- Taysha Gene Therapies' 5-year Consolidated Net Income high stood at -$15.0 million for Q4 2023, and its period low was -$55.1 million during Q4 2022.
- Moreover, its 4-year median value for Consolidated Net Income was -$23.8 million (2024), whereas its average is -$26.7 million.
- As far as peak fluctuations go, Taysha Gene Therapies' Consolidated Net Income surged by 7269.39% in 2023, and later tumbled by 4336.02% in 2024.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Consolidated Net Income stood at -$55.1 million in 2022, then soared by 72.69% to -$15.0 million in 2023, then dropped by 21.39% to -$18.3 million in 2024, then tumbled by 69.11% to -$30.9 million in 2025.
- Its Consolidated Net Income stands at -$30.9 million for Q3 2025, versus -$24.9 million for Q2 2025 and -$20.1 million for Q1 2025.